Pharma News

The AstraZeneca employee fraud case involves sales personnel in China who allegedly forged or altered tumor gene testing reports to defraud the national Medicare fund, particularly concerning AstraZeneca's lung cancer treatment drug, Tagrisso.

Currently, Musk has not detailed how to achieve this goal, but analysts expect that as these drugs may soon qualify for price negotiations under Medicare, this could be a potential avenue for reducing their costs.

For pharmaceutical representatives, 2025 presents both challenges and opportunities, and the standardized development of the industry will bring new career prospects. In the face of challenges, representatives must enhance their professional qualities and

Recently, investigations by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) have put pharmaceutical giants AstraZeneca and GlaxoSmithKline (GSK) in the spotlight. This incident not only reveals the strictness of compliance overseas but

As President Donald J. Trump gradually assembles his cabinet, the appointments of new officials may signal a positive trend for the biopharmaceutical industry over the next four years.

At the first-ever CPhI (Convention on Pharmaceutical Ingredients) conference held in the Middle East, two Saudi Arabian institutions signed an agreement with Vertex Pharmaceuticals aimed at enhancing the country’s production capacity in the field of gene

In recent years, Gilead Sciences' most profitable product, Biktarvy, has been the flagship of the company. However, as the patent for this HIV medication is set to expire in 2033, Gilead has unveiled a highly praised strategy at its HIV investor conferenc

On the evening of December 11, 2024, China Resources Double Crane Pharmaceutical Co., Ltd. announced that its independent director, Mr. Yu Shunkun, recently received a warning letter from the Beijing Regulatory Bureau of the China Securities Regulatory Co

Recently, Hanyu Pharmaceutical Co., Ltd. announced that its former president, Yuan Jiancheng, has been sentenced to three years and six months in prison for embezzlement.

These two companies will operate under Fuller's Health Care, Medical, and Consumer Adhesives Global Business Division (HHC). With a total acquisition price of €180 million, the valuation of these two acquisitions is 15.5 times the pre-synergy EBITDA and i

According to information from the U.S. clinical trial registry Clinicaltrials on December 10, Chinese company Heng Rui Pharma has launched its first Phase III clinical trial (SHR-1918-301) for the ANGPTL3 monoclonal antibody SHR-1918.

Merck acquired VelosBio for $2.75 billion in November 2020, gaining its ROR1 ADC drug, zilovertamab vedotin (VLS-101), which was then in early clinical development and had received orphan drug designation (ODD) and fast track designation (FTD) from the U.

According to the official announcement, AstraZeneca commits to providing a cash reward of 10% of the annual salary for employees below the managerial level, while those at the managerial level and above will receive a 20% equity incentive.

In recent years, among the new anesthetic sedation drugs launched on the market, Remazolam has undoubtedly aroused widespread concern in the industry.

With the arrival of winter and the drop in temperature, the active period of respiratory pathogens has arrived. According to recent surveillance data from the Chinese Center for Disease Control and Prevention, a variety of pathogens are causing acute resp

GlaxoSmithKline (GSK) has signed an exclusive licensing agreement with Eucure Biopharma, under which GSK acquires the rights to develop and commercialize the ADC drug DB-1324 globally, excluding mainland China, Hong Kong, and Macau.

AstraZeneca officially announced on the evening of December 4 that Ms. Iskra Reic has been appointed as Executive Vice President and Head of International Business, succeeding Mr. Wang Lei, who has temporarily stepped down to cooperate with related invest

As of the latest official reports, the personnel involved in the AstraZeneca medical insurance fraud case have not mentioned patients or doctors. However, this protracted "insurance fraud" case has yet to reach a conclusion.

Researchers interested in finding partners in the UK or South Korea are invited to submit expressions of interest before the program launches in January 2025.

According to Reuters, eight sources have revealed that the world’s top hedge funds are actively recruiting medical professionals, including doctors, scientists, and analysts, to provide in-depth expert analysis on the future trends of pharmaceutical stock